Golimumab as the first monthly subcutaneous fully human anti-TNF-α antibody in the treatment of inflammatory arthropathies

Immunotherapy

Volumn 2, Issue 4, 2010, Pages 453-460

  Hutas, Gabor ^a  

^a SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

human monoclonal antibody; monthly subcutaneous injection; rheumatoid arthritis; SmartJect autoinjector; TNF ; transgenic

Indexed keywords

DISEASE MODIFYING ANTIRHEUMATIC DRUG; GOLIMUMAB; METHOTREXATE; PLACEBO; SIMPONI; UNCLASSIFIED DRUG;

ANKYLOSING SPONDYLITIS; ARTHROPATHY; CLINICAL TRIAL; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; HISTOPLASMOSIS; HUMAN; IN VITRO STUDY; INFECTION; INFLAMMATORY ARTHROPATHY; INJECTION SITE REACTION; LYMPHOMA; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; REVIEW; RHEUMATOID ARTHRITIS; SKIN CANCER; SOLID TUMOR; TREATMENT WITHDRAWAL; TUBERCULOSIS;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CLINICAL TRIALS, PHASE III AS TOPIC; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; HUMANS; INJECTIONS, SUBCUTANEOUS; MICE; RECOMBINANT PROTEINS; SAFETY; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77954975093     PISSN: 1750743X     EISSN: None     Source Type: Journal    
DOI: 10.2217/imt.10.34     Document Type: Review

References (36)

1. Laursen T, Hansen B, Fisker S: Pain perception after subcutaneous injections of media containing different buffers. Basic Clin. Pharmacol. Toxicol. 98(2), 218-221 (2006).
2. Shealy D, Cai A, Lacy E et al.: Characterization of golimumab (CNTO 148), a novel fully human monoclonal antibody specific for human TNF-α. Arthritis rheum. 56(9) S155 (2007).
3. Martin PL, Martin L, Oneda S, Treacy G: Effects of anti-TNF-α monoclonal antibody, administered throughout pregnancy and lactation, on the development of the macaque immune system. Am. J. Repr. Immunol. 58, 138-149 (2007).
4. Zhou H, Jang H, Fleischmann RM et al.: Pharmacokinetics and safety of golimumab, a fully human anti-TNF-α monoclonal antibody in subjects with rheumatoid arthritis. J. Clin. Pharmacol. 47, 383-396 (2007).
5. Kay J, Matteson EL, Dasgupta B et al.: Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: a randomized, double-blind, placebo-controlled, dose-ranging study. Arthritis Rheum. 58(4), 964-975 (2008).
6. Keystone EC, Genovese MC, Klareskog L et al.: Golimumab, a human antibody to tumour necrosis factor a given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study. Ann. Rheum. Dis. 68(6), 789-796 (2009).
7. Genovese MC, Keystone EC, Hsia EC et al.: Golimumab significantly improves physical function, health-related quality of life, and fatigue in rheumatoid arthritis patients: results from the GO-FORWARD study. ACR/ARHP Annual Scientific Meeting. Abstract 1035 (2008).
8. Keystone EC, Genovese MC, Rahman MU et al.: Golimumab in rheumatoid arthritis: GO-FORWARD Week 52 results. ACR/ARHP Annual Scientific Meeting. Abstract 1667 (2009).
9. Smolen JS, Kay J, Doyle MK et al.: Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor a inhibitors (GO-AFTER study): a multicentre, randomized, double-blind, placebo-controlled, Phase III trial. Lancet 374(9685), 210-221 (2009).
10. Smolen JS, Doyle MK, Kay J et al.: Golimumab is efficacious in anti-TNF agent experienced patients with active rheumatoid arthritis regardless of type of agent or reason for discontinuation of prior anti-TNF agent: results from the GO-AFTER study. European League Against Rheumatism (EULAR). Abstract THU0209 (2009).
11. Smolen JS, Kay J, Doyle MK et al.: Golimumab in rheumatoid arthritis patients previously treated with anti-TNFa agents (GO-AFTER study): week 52 results. ACR/ARHP Annual Scientific Meeting. Abstract 1669 (2009).
12. Kay J, Doyle MK, Smolen J et al.: Golimumab significantly improves physical function and fatigue in RA patients previously treated with anti-TNFa agents: results from the GO-AFTER study. ACR/ARHP Annual Scientific Meeting. Abstract 1035 (2008).
13. Emery P, Fleischmann R, Desire MFM et al.: Golimumab and radiographic progression in rheumatoid arthritis: results of GO-BEFORE and GO-FORWARD studies. ACR/ARHP Annual Scientific Meeting. Abstract 640 (2009).
14. Braun J, Davis JC, Van der Heijde D et al.: Golimumab, a new human TNF-α antibody administered as a monthly subcutaneous injection in ankylosing spondylitis (AS): 24-week efficacy and safety results of the randomized, placebo-controlled GO-RAISE study. Arthritis Rheum. 56(12), 4236-4237 (2007).
15. Inman RD, Davis JC Jr, van der Heijde D et al.: Efficacy and safety of golimumab in patients with ankylosing spondylitis. Results of a randomized, double-bind, placebo-controlled, Phase III trial. Arthritis Rheum. 58(1), 3402-3412 (2008).
16. Braun J, van der Heijde D, Deodhar A et al.: Golimumab, a new, humanm TNF-α antibody administered subcutaneously every 4 weeks, in ankylosing spondylitis (AS): 104-week efficacy and safety results of the randomized, placebo-controlled GO-RAISE study. Ann. Rheum. Dis. 68(Suppl. 3), 629 (2009).
17. Deodhar A, Braun J, Inman RD et al.: Golimumab significantly improves sleep in patients with active ankylosing spondylitis: Results from the phase 3 GO-RAISE study. Ann. Rheum. Dis. 67(Suppl. II), Abstract 383 (2008).
18. Braun J, Inman R, van der Heijde D et al.: Golimumab significantly improves productivity in patients with active ankylosing spondylitis: results from the Phase 3 GO-RAISE study. Ann. Rheum. Dis. 67(Suppl. II) Abstract 381 (2008).
19. van der Heide D, Braun J, Davis JC et al.: Head-to head comparison of 3 enthesitis indices in the ankylosing spondylitis anti-TNF-α trial of golimumab (GO-RAISE). European League Against Rheumatism (EULAR) Annual Meeting. Abstract SAT0272 (2008).
20. Visvanathan S, Inman RD, Braun J et al.: Identification of serum markers associated with improvement in clinical response measures in as patients treated with golimumab. Ann. Rheum. Dis. 67(Suppl. II) Abstract 520 (2008).
21. Kavanaugh A: Golimumab, a new, human, TNF-α antibody administered as a monthly subcutaneous injection in psoriaticarthritis: 24-week efficacy and safety results of the randomized, placebo-controlled GO-REVEAL study. ACR/ARHP Annual Scientific Meeting. Abstract L14 (2007).
22. Gladman D, Kavanaugh A, McInnes I et al.: Golimumab, a new human TNF-α antibody, administered every 4 weeks as a subcutaneous injection in psoriatic arthritis: nail, enthesitis, and dactylitis response in the randomized, placebo-controlled, GO-REVEAL study. Ann. Rheum. Dis. 67(Suppl. II), Abstract 526 (2008).
23. Mease P, McInnes I, Krueger GG et al.: Golimumab significantly improves physical function, health-related quality of life, productivity, and reduces time lost from work for caregivers in patients with active psoriatic arthritis. Ann. Rheum. Dis. 67(Suppl. II), Abstract 572 (2008).
24. Kavanaugh A, van der Heide D, Gladman D et al.: Golimumab inhibits progression of radiographic damage in patients with psoriatic arthritis: 52 week results from the GO-REVEAL study. ACR/ARHP Annual Meeting. Abstract LB5 (2009).
25. Visvanathan S, Gladman D, Brodmerkel C et al.: Identification of serum markers associated with improvement in clinical response measures in psoriatic arthritis patients treated with golimumab. Ann. Rheum. Dis. 67(Suppl. II), Abstract 533 (2008).
26. Visvanathan S, Inman RD, Braun J et al.: Identification of serum markers associated with improvement in clinical response measures in AS patients treated with golimumab. Ann. Rheum. Dis. 67 (Suppl. II), 520 (2008)
27. Xu Z, Vu T, Lee H et al.: Population pharmacokinetics of golimumab, an anti-tumour necrosis factor-α human monoclonal antibody in patients with psoriatic arthritis. J. Clin. Pharmacol. 49(9), 1056-1070 (2009).
28. Kavanaugh A, Mease P, Krueger GG et al.: Golimumab, a new, human TNF-α antibody, administered subcutaneously every 4 weeks in psoriatic arthritis patients: 104-week efficacy and safety results of the randomized, placebo-controlled GO-REVEAL study. Ann. Rheum. Dis. 68(Suppl. 3), 136 (2009).
29. Xu Z, Vu T, Lee H et al.: Population pharmacokinetics of golimumab, an anti-tumour necrosis factor-α human monoclonal antibody in patients with psoriatic arthritis. J. Clin. Pharmacol. 49(9), 1056-1070 (2009).
30. Kavanaugh A, Mease P, Krueger GG et al.: Golimumab, a new, human TNF-α antibody, administered subcutaneously every 4 weeks in psoriatic arthritis patients: 104-week efficacy and safety results of the randomized, placebo-controlled GOREVEAL study. Ann. Rheum. Dis. 68(Suppl. 3), 136 (2009).
31. McInnes I, Kavanaugh A, Krueger GG et al.: Golimumab, a new human TNF-α antibody, administered every 4 weeks as a subcutaneous injection in psoriatic arthritis: response to pneumococcal vaccine in the randomized, placebo-controlled, GO-REVEAL study. Ann. Rheum. Dis. 67(Suppl. II), Abstract 529 (2008).
32. Furst DE, Dolye MK, Kay J et al.: Golimumab, a new human anti-TNFa monoclonal antibody administered subcutaneously every 4 weeks, improves anaemia and well-being in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. Ann. Rheum. Dis. 67(Suppl. II), Abstract 181 (2008).
33. Brightling C, Berry M, Amrani Y: Targeting TNF-α: a novel therapeutic approach for asthma. J. Allergy Clin. Immunol. 121(1), 5-10 (2008).
34. Kay J, Fleischmann RM, Keystone EC et al.: Safety of golimumab, a new human anti-TNFa antibody, in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: an analysis of pooled data from randomized, double-blind, placebo-controlled studies. ACR/ARHP Annual Scientific Meeting. Presentation No.790 (2009).
35. Scott DW, De Groot AS: Can we prevent immunogenicity of human protein drugs? Ann. Rheum. Dis. 69(Suppl. I), I72-I78 (2010).
36. Clinicaltrials.gov main Page www.clinicaltrials.gov